Remove Exercise Remove Hypertension Remove Innovation
article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment,” said Chris Giordano , President & Chief Executive Officer of Tenax Therapeutics. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

How Wearable Tech Can Help Monitor Your Heart Health

MIBHS

By identifying patterns, users can understand how their heart responds to exercise, stress, or relaxation. Tracking Physical Activity and Exercise Physical activity is vital for maintaining heart health, and wearable tech provides detailed metrics on steps taken, calories burned, and active minutes.

article thumbnail

Abstract 4142839: Modulating the Intestinal Mycobiome Mitigates Pulmonary Arterial Hypertension Severity

Circulation

Introduction:Inflammation is a key driver in the development of pulmonary arterial hypertension (PAH). Recent studies have indicated that modulating the intestinal microbiome may be an innovative approach to mitigate systemic inflammation in PAH. Circulation, Volume 150, Issue Suppl_1 , Page A4142839-A4142839, November 12, 2024.

article thumbnail

National AFib Awareness Month: A Call to Action for Physicians Worldwide

ADN Center of Excellence

Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase. From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving.

AFIB 59
article thumbnail

National AFib Awareness Month: A Call to Action for Physicians Worldwide

ADN Center of Excellence

Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase. From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving.

AFIB 52
article thumbnail

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

ET Main Tent (Hall B1) Effect of Gamification, Financial Incentives or Both Combined to Increase Physical Activity Among Patients with Elevated Risk For Major Adverse Cardiovascular Events.

article thumbnail

Corvia atrial shunt system: Mean LA pressure reduction device in HFpEF

Dr. S. Venkatesan MD

It is prudent to understand, that even in systolic LV failure; it is the raised LVEDP that causes the symptoms and marks the limits of exercise capacity. May be, it will come soon in the innovative lanes of cardiology. Curious minds might ask, can’t we decompress LV it self by creating a small VSD.